Madison-based Immuto Scientific, a biotechnology company providing drug discovery services, is the recipient of a $2.5 million Small Business Innovation Research (SBIR) Phase II grant from the National Institutes of Health (NIH).

Immuto Scientific’s Plasma Induced Modification of Biomolecules (PLIMB) technology helps companies understand how effectively a drug binds to its target to improve the effectiveness of the drug.

The company provides analytical research services to pharmaceutical companies using technologies to help accelerate drug discovery and enable the development of highly effective therapeutics.

Click here to read the full article.